PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 128 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $100 | -100.0% | 9,199 | -93.3% | 0.00% | -100.0% |
| Q3 2022 | $1,155,000 | +273.8% | 137,200 | +793.9% | 0.01% | +500.0% |
| Q4 2020 | $309,000 | -83.6% | 15,349 | -90.2% | 0.00% | -87.5% |
| Q3 2019 | $1,885,000 | -38.3% | 156,961 | -35.4% | 0.01% | -38.5% |
| Q1 2019 | $3,053,000 | +77.0% | 242,862 | -5.2% | 0.01% | +44.4% |
| Q4 2018 | $1,725,000 | -32.9% | 256,220 | +2.6% | 0.01% | -18.2% |
| Q3 2018 | $2,570,000 | +63.5% | 249,704 | +6.8% | 0.01% | +57.1% |
| Q2 2018 | $1,572,000 | +215.7% | 233,830 | +303.3% | 0.01% | +250.0% |
| Q1 2018 | $498,000 | +152.8% | 57,981 | +513.0% | 0.00% | +100.0% |
| Q4 2017 | $197,000 | – | 9,459 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |